Everyone is a leader at Mylan. Each employee is asked to define their role in moving our mission forward and to Lead, Learn, Teach and Perform every day with the right Attitude. Our senior team leads by example and sets high standards for us to follow a challenge we are happy to meet. Guided by the principles of our mission, our senior leaders have been relentless in their desire to break down the barriers that impede the progress of providing all 7 billion of us access to quality medicine, and to ultimately change the world. The example they set is your platform to making your mark, making a difference and making better health for a better world a reality.

Heather Bresch,
Chief Executive Officer

Heather Bresch began her career with Mylan as a data-entry clerk, rising through the ranks and eventually becoming Mylan’s president before taking on the CEO role.

Among her many accomplishments at Mylan, Heather led the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business.

Heather is a leading advocate for global quality standards, and was instrumental in the development of the Generic Drug User Fee Amendments, which hold all drugs sold in the U.S. to one quality standard.

In addition, Heather has championed changes to the Federal Food, Drug and Cosmetic Act to support the FDA with the resources to regularly inspect U.S. and foreign plants at the same rate.

She has also worked diligently for accelerated approval paths for safe, effective generic versions of biologic drugs, which provide patients access to lower-cost versions of many lifesaving medicines and products.

In addition, Heather is continually raising awareness about life-threatening allergic reactions, and has been on the forefront for programs that provide immediate access to epinephrine auto-injectors – the first line of treatment for anaphylaxis.

Show Less

Robert J. Coury,
Executive Chairman

Under Robert’s visionary leadership, Mylan has risen from the third largest generics pharmaceutical company in the U.S. to becoming one of the largest pharmaceutical companies in the world, with a respected ranking on both the S&P 500 and the Fortune 500.

Since 2007, Robert has led the company through numerous transactions, which have transformed Mylan into a global powerhouse in the highly competitive pharmaceutical industry.

Before assuming his current role in 2012, Robert developed a powerful leadership team at Mylan, recruiting executive talent from within and outside the company. This internal strategy has enabled the company to achieve even greater growth and success.

Thanks to Robert’s vision and insight, Mylan’s is accomplishing its mission of providing the world’s 7 billion people with access to high quality medicine.

Show Less

Rajiv Malik,
President

Rajiv is responsible for Mylan’s daily operations, including R&D, business development, regulatory affairs, manufacturing, quality, supply chain and medical affairs, as well as sales and marketing. He also is responsible for helping lead Mylan’s expansion into emerging and other new markets, such as the company’s commercial launch in India in 2012.

Rajiv played a key role in expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. He also helped establish Mylan as a leader in antiretroviral medicines, particularly in developing markets.

With more than 60 patents to his credit, Rajiv has over 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, he was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D.

Show Less